Viridian Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Steve Mahoney

Chief executive officer

US$13.0m

Total compensation

CEO salary percentage	0.9%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	3.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve Mahoney's remuneration changed compared to Viridian Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$218m
Dec 31 2023	US$13m	US$113k	-US$238m

Compensation vs Market: Steve's total compensation ($USD13.02M) is above average for companies of similar size in the UK market ($USD1.36M).

Compensation vs Earnings: Insufficient data to compare Steve's compensation with company performance.

CEO

Steve Mahoney (53 yo)

less than a year

Tenure

US$13,022,654

Compensation

Mr. Stephen F. Mahoney, also known as Steve, J. D. serves as President, CEO & Director at Viridian Therapeutics, Inc. since October 30, 2023. He served as President, Chief Financial and Operating Officer a...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Stephen Mahoney	CEO, President & Director	less than a year	US$13.02m	no data
Seth Harmon	Senior VP of Finance and Accounting	less than a year	US$6.67m	0.0016% $ 12.2k
Thomas Beetham	Chief Operating Officer	less than a year	US$5.17m	no data
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	no data	no data
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	no data	no data
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	no data	no data
Vahe Bedian	Co-Founder & Scientific Advisor	no data	no data	no data
Jennifer Tousignant	Chief Legal Officer	less than a year	no data	no data
John Jordan	Vice President of Investor Relations & Corporate Communications	no data	no data	no data
Anthony Casciano	Chief Commercial Officer	1.2yrs	no data	no data
Thomas Ciulla	Chief Medical Officer	1.4yrs	no data	0.0012% $ 9.3k
Shan Wu	Chief Business Officer	less than a year	no data	no data

0.7yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 0K1R's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Stephen Mahoney	CEO, President & Director	less than a year	US$13.02m	no data
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	no data	no data
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	no data	no data
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	no data	no data
Arlene Morris	Independent Director	6.4yrs	US$477.83k	0% $ 0
Victor Ambros	Scientific Advisory Board Member	no data	no data	no data
Stefanie Dimmeler	Scientific Advisory Board Member	no data	no data	no data
Jeffery Molkentin	Scientific Advisory Board Member	no data	no data	no data
Eva van Rooij	Scientific Advisory Board Member	no data	no data	no data
Tomas Kiselak	Independent Chairperson of Board	3.7yrs	US$503.83k	0% $ 0
Jennifer Moses	Independent Director	2.9yrs	US$467.83k	0% $ 0
Peter Harwin	Independent Director	3.7yrs	US$471.83k	0% $ 0

3.7yrs

Average Tenure

53yo

Average Age

Experienced Board: 0K1R's board of directors are considered experienced (3.7 years average tenure).

Viridian Therapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Resignation of Kristian Humer as Chief Financial Officer

Recent updates

First quarter 2024 earnings released: US$0.79 loss per share (vs US$1.61 loss in 1Q 2023)

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New major risk - Shareholder dilution

Full year 2023 earnings released: US$5.31 loss per share (vs US$4.05 loss in FY 2022)

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Third quarter 2023 earnings released: US$1.09 loss per share (vs US$0.86 loss in 3Q 2022)

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Resignation of Kristian Humer as Chief Financial Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$1.27 loss per share (vs US$1.06 loss in 2Q 2022)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

First quarter 2023 earnings released: US$1.61 loss per share (vs US$0.98 loss in 1Q 2022)

President recently bought US$101k worth of stock

President recently bought US$160k worth of stock

Full year 2022 earnings released: US$4.05 loss per share (vs US$6.66 loss in FY 2021)

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

High number of new and inexperienced directors

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

Third quarter 2022 earnings released: US$0.86 loss per share (vs US$1.26 loss in 3Q 2021)

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

High number of new and inexperienced directors

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$2.22 loss in 2Q 2021)

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

High number of new and inexperienced directors

Viridian Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

High number of new and inexperienced directors

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

Viridian Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

Viridian Therapeutics, Inc. announced that it expects to receive $75 million in funding from Hercules Capital, Inc.

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

High number of new and inexperienced directors

Viridian Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

High number of new and inexperienced directors

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

High number of new and inexperienced directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age